GSK5764227 + pembrolizumab

GSK5764227 + pembrolizumab is a **combination of an investigational antibody-drug conjugate (GSK5764227, a B7-H3-targeted ADC) and the anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA)**. GSK5764227 is composed of a fully humanized monoclonal antibody targeting B7-H3, covalently linked via a protease-cleavable linker to a topoisomerase I inhibitor payload. It is designed to selectively target and kill B7-H3-expressing tumor cells, leveraging both direct cytotoxicity and immune modulation[2][4]. Pembrolizumab is a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2, thereby promoting T-cell-mediated anti-tumor responses[7]. The combination is being investigated for **advanced solid tumors and relapsed/refractory cancers**, where synergistic effects of targeted cytotoxicity and immune checkpoint blockade may enhance anti-tumor efficacy[3].

Other names

GSK-227GSK227GSK 227GSK B7-H3 ADChuman anti–B7-H3 ADCanti–B7-H3 ADCPembrolizumab